Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARWRNASDAQ:GMTXNASDAQ:OPTNASDAQ:VCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARWRArrowhead Pharmaceuticals$16.39+2.0%$13.39$9.57▼$30.41$2.27B0.891.52 million shs1.15 million shsGMTXGemini Therapeutics$46.68-0.4%$45.20$1.16▼$14.10$2.02B-0.12189,291 shs437,325 shsOPTOpthea$3.41$3.41$1.79▼$6.30$524.84M1.1226,856 shsN/AVCELVericel$40.44-2.1%$41.52$37.39▼$63.00$2.04B1.31416,209 shs710,256 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARWRArrowhead Pharmaceuticals0.00%+6.15%+11.37%-9.32%-30.02%GMTXGemini Therapeutics0.00%-1.46%-6.04%-16.91%+37.50%OPTOpthea0.00%0.00%0.00%-33.27%+20.07%VCELVericel0.00%+2.27%+7.45%-15.47%-12.26%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARWRArrowhead Pharmaceuticals3.4576 of 5 stars3.32.00.03.41.62.50.0GMTXGemini TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOPTOpthea0.6665 of 5 stars2.10.00.00.01.30.80.6VCELVericel3.1245 of 5 stars3.53.00.00.02.80.81.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARWRArrowhead Pharmaceuticals 2.67Moderate Buy$42.13157.09% UpsideGMTXGemini Therapeutics 0.00N/AN/AN/AOPTOpthea 2.17Hold$1.33-60.90% DownsideVCELVericel 3.00Buy$61.1451.18% UpsideCurrent Analyst Ratings BreakdownLatest OPT, ARWR, VCEL, and GMTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025VCELVericelStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$67.00 ➝ $67.005/20/2025ARWRArrowhead PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.005/13/2025ARWRArrowhead PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$21.00 ➝ $17.005/13/2025ARWRArrowhead PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/11/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$61.00 ➝ $51.003/25/2025OPTOptheaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$12.00 ➝ $2.003/25/2025OPTOptheaLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$12.00 ➝ $1.003/25/2025OPTOptheaJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Underperform$8.00 ➝ $1.003/24/2025OPTOptheaLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/24/2025OPTOptheaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/3/2025VCELVericelTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$67.00 ➝ $61.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARWRArrowhead Pharmaceuticals$545.21M4.15N/AN/A$1.54 per share10.64GMTXGemini TherapeuticsN/AN/AN/AN/A$2.89 per shareN/AOPTOpthea$87.67K5,986.77N/AN/A($0.56) per share-6.09VCELVericel$238.54M8.54$0.01 per share3,081.95$4.73 per share8.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARWRArrowhead Pharmaceuticals-$599.49M-$1.40N/AN/AN/AN/A-236.60%-64.09%8/7/2025 (Estimated)GMTXGemini Therapeutics-$71.87M-$1.00N/AN/AN/AN/A-38.78%-35.88%N/AOPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/AN/AVCELVericel-$3.18M$0.03674.1891.92N/A1.56%1.48%0.96%7/30/2025 (Estimated)Latest OPT, ARWR, VCEL, and GMTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q2 2025ARWRArrowhead Pharmaceuticals-$0.06$2.75+$2.81$2.75$116.27 million$542.71 million5/8/2025Q1 2025VCELVericel-$0.09-$0.23-$0.14-$0.23$53.86 million$52.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AGMTXGemini TherapeuticsN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/AVCELVericelN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARWRArrowhead Pharmaceuticals7.276.096.09GMTXGemini TherapeuticsN/A71.4971.49OPTOptheaN/A2.942.94VCELVericelN/A4.614.23Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARWRArrowhead Pharmaceuticals62.61%GMTXGemini Therapeutics75.42%OPTOpthea55.95%VCELVericelN/AInsider OwnershipCompanyInsider OwnershipARWRArrowhead Pharmaceuticals4.30%GMTXGemini Therapeutics12.90%OPTOpthea3.20%VCELVericel5.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARWRArrowhead Pharmaceuticals400138.10 million120.68 millionOptionableGMTXGemini Therapeutics3043.33 million37.74 millionNot OptionableOPTOpthea8153.91 million148.98 millionNot OptionableVCELVericel30050.34 million46.79 millionOptionableOPT, ARWR, VCEL, and GMTX HeadlinesRecent News About These CompaniesWellington Management Group LLP Buys 701,064 Shares of Vericel Co. (NASDAQ:VCEL)May 30 at 6:12 AM | marketbeat.comVoloridge Investment Management LLC Acquires Shares of 27,345 Vericel Co. (NASDAQ:VCEL)May 30 at 4:02 AM | marketbeat.comVericel (NASDAQ:VCEL) Earns Overweight Rating from StephensMay 25, 2025 | americanbankingnews.comVericel's (VCEL) Overweight Rating Reiterated at StephensMay 24, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Shares Purchased by Deutsche Bank AGMay 24, 2025 | marketbeat.com5VCEL : What Analysts Are Saying About Vericel StockMay 23, 2025 | benzinga.comVericel Co. (NASDAQ:VCEL) Stock Position Cut by BNP Paribas Financial MarketsMay 23, 2025 | marketbeat.comRafferty Asset Management LLC Lowers Stake in Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comLazard Asset Management LLC Purchases 5,923 Shares of Vericel Co. (NASDAQ:VCEL)May 22, 2025 | marketbeat.comSoleus Capital Management L.P. Purchases Shares of 80,696 Vericel Co. (NASDAQ:VCEL)May 21, 2025 | marketbeat.comVericel Co. (NASDAQ:VCEL) Holdings Raised by D. E. Shaw & Co. Inc.May 20, 2025 | marketbeat.comAmeriprise Financial Inc. Sells 124,122 Shares of Vericel Co. (NASDAQ:VCEL)May 19, 2025 | marketbeat.comVericel at BofA Securities Conference: Growth and Innovation in HealthcareMay 17, 2025 | investing.comVericel Co. (NASDAQ:VCEL) Given Consensus Rating of "Buy" by BrokeragesMay 15, 2025 | marketbeat.comStockNews.com Downgrades Vericel (NASDAQ:VCEL) to SellMay 15, 2025 | marketbeat.comNorthern Trust Corp Buys 44,397 Shares of Vericel Co. (NASDAQ:VCEL)May 13, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of Vericel Q4 EarningsMay 13, 2025 | marketbeat.comVericel (NASDAQ:VCEL) Issues Earnings ResultsMay 12, 2025 | marketbeat.comFirst Trust Advisors LP Lowers Stock Holdings in Vericel Co. (NASDAQ:VCEL)May 12, 2025 | marketbeat.comFrontier Capital Management Co. LLC Has $15.82 Million Stock Holdings in Vericel Co. (NASDAQ:VCEL)May 11, 2025 | marketbeat.comWhich Is a Better Investment, BioCryst Pharmaceuticals, Inc. or Vericel Corporation Stock?May 10, 2025 | aaii.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Pushes Back on Short Seller Case With Strong EarningsBy Nathan Reiff | May 14, 2025View D-Wave Pushes Back on Short Seller Case With Strong EarningsCrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodBy Chris Markoch | May 20, 2025View CrowdStrike’s Rally Faces a Test—Here’s Why That’s GoodQuantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?By Jeffrey Neal Johnson | May 22, 2025View Quantum Quandary: Is D-Wave a Calculated Play or Leap of Faith?Here's Why Call Option Traders Love Dutch Bros Stock By Gabriel Osorio-Mazilli | May 12, 2025View Here's Why Call Option Traders Love Dutch Bros Stock Lyft: Profitability Milestone and Buyback Fuel Investor OptimismBy Jeffrey Neal Johnson | May 13, 2025View Lyft: Profitability Milestone and Buyback Fuel Investor OptimismOPT, ARWR, VCEL, and GMTX Company DescriptionsArrowhead Pharmaceuticals NASDAQ:ARWR$16.39 +0.32 (+1.96%) Closing price 03:59 PM EasternExtended Trading$16.40 +0.01 (+0.06%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Gemini Therapeutics NASDAQ:GMTX$46.68 -0.19 (-0.41%) As of 05/30/2025Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Opthea NASDAQ:OPT$3.41 0.00 (0.00%) As of 05/30/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Vericel NASDAQ:VCEL$40.48 -0.82 (-1.99%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
